Topological Analysis of Single-Cell Hierarchy Reveals Inflammatory Glial Landscape of Macular Degeneration

Obesity Hormone Function in Aging Eyes: Linking Adiponectin and its Receptors to AMD

“…We conducted an in-depth analysis of cellular heterogeneity and landscape using the Seurat package [78] by plotting UMAP (Uniform Manifold Approximation and Projection). Furthermore, we identified distinct cell types using the corresponding marker genes (Figure 1A and B) as previously reported by Kuchroo et al [79]. By employing the marker genes, we were able to distinguish various types of neuronal cells, such as retinal ganglion cells, horizontal cells, bipolar cells, rod photoreceptors, cone photoreceptors, and amacrine cells, in addition to uncovering infrequent non-neuronal cell types, such as microglia, astrocytes, and Müller glia.…”

Emerging Co‐Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization

“…[5] Therefore, the development of high compliance strategies based on noninvasive drug delivery techniques and long-term sustained-release and multifunctional formulations to effectively combat the complex pathogenesis of AMD is urgently needed. [6] Recently, various novel strategies or drugs have been developed for AMD treatment by inhibiting the complement pathway, [7,8] targeting the progression of fibrosis, [9,10] reducing the metabolism, [11] and deposition of lipofuscin precursors, neutralizing oxidative stress, [12] alleviating hypoxic levels, [13] improving vascular stability to inhibit pathological angiogenesis, [14][15][16][17] reducing intraocular chronic inflammation, [18][19][20][21] and so on. Nintedanib is a first-line drug used to treat pulmonary fibrosis by inhibiting nonreceptor tyrosine kinases and multiple receptor tyrosine kinases and also acts as an effective inhibitor for vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR).…”